Novo Nordisk A/S
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Maziar Mike Doustdar
- Full Time Employees
- 77,406
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- Novo Alle 1 Bagsvaerd CR Denmark 2880
- IPO Date
- Apr 30, 1981
- CIK
- 0000353278
- Website
- novonordisk.com
- Similar Companies
- Business
- Novo Nordisk A/S, a leading global healthcare company founded in 1923 and headquartered in Bagsværd, Denmark, develops, manufactures and markets pharmaceutical products and services focused on diabetes care, obesity management, rare blood disorders, growth hormone therapy and hormone replacement therapy; its core offerings include GLP-1 receptor agonists such as semaglutide branded as Ozempic and Rybelsus for type 2 diabetes and Wegovy for obesity, insulins including rapid-acting NovoLog/NovoRapid, long-acting Tresiba and Levemir, and human insulins like Novolin R, alongside hemostasis products such as NovoSeven and NovoEight for hemophilia, and growth hormone therapies; the company operates production facilities in nine countries, employs over 76,000 people and markets its products in approximately 170 countries worldwide, with majority control held by Novo Holdings A/S, a wholly owned entity of the Novo Nordisk Foundation. Recent strategic developments include the October 2025 acquisition of Akero Therapeutics for up to $5.2 billion to bolster its metabolic dysfunction-associated steatohepatitis (MASH) pipeline, a May 2025 partnership and licensing agreement with Septerna potentially worth $2.2 billion for oral small molecule therapies targeting obesity, type 2 diabetes and cardiometabolic disorders, a December 2024 collaboration with Photys Therapeutics for up to $186 million in proximity-based therapeutics for cardiometabolic targets, filing for FDA approval of a higher 7.2 mg dose of Wegovy injection in November 2025, positive phase 2 results for amycretin showing significant weight loss and HbA1c reduction in type 2 diabetes patients in November 2025, and workforce reduction of 9,000 positions or about 9% globally in September 2025 amid competitive pressures from generic entrants; the company continues expanding manufacturing capacity, including a $4.1 billion semaglutide plant in Clayton, North Carolina announced in June 2024 and acquisition of Catalent sites, while appointing Maziar Mike Doustdar as CEO effective August 2025.
NVO Rallies 11% in a Month: How Should Investors Play the Stock?
Novo Nordisk A/S (NVO) is Attracting Investor Attention: Here is What You Should Know
Novo Nordisk's Wegovy Pill Escalates Eli Lilly Rivalry
3 High Growth GLP-1 Biotech Winners to Buy in July
Novo Nordisk: Why I Don't Think The Story Is Broken
Novo Nordisk launches weekly insulin Awiqli in India as diabetes burden rises
Novo Nordisk (NVO) Dips More Than Broader Market: What You Should Know
Novo Nordisk shares dip as latest prescription data points to GLP-1 pill slowdown
Novo Nordisk shares dip as latest prescription data points to GLP-1 pill slowdown
Leading bank backs European pharma as the cleaner alternative to the AI trade
3 Reasons to Buy Novo Nordisk Stock
2 Dirt Cheap Healthcare Stocks to Buy in July
The Anti-Magnificent Seven Trade? VGK Is Quietly Creeping Toward Record Highs
Eli Lilly and vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026?
Could This Healthcare Stock Help You Build a Real Fortune Over the Next 20 Years?
Novo Nordisk: The Stock Price Is Only Beginning To Catch Up With Business Fundamentals
Can Medicare Bridge Help Novo Nordisk Defend Its GLP-1 Leadership?
Novo Nordisk AS (NVO) Stock Up 3.4% and Still Undervalued -- GF Score: 76/100
Microsoft to invest $2.5B in new AI implementation business
Novo Nordisk (NVO) Ascends While Market Falls: Some Facts to Note